HK1072375A1 - Use of the neurotoxic component of botulinum toxin for treating smooth muscle disorders - Google Patents

Use of the neurotoxic component of botulinum toxin for treating smooth muscle disorders

Info

Publication number
HK1072375A1
HK1072375A1 HK05105116.3A HK05105116A HK1072375A1 HK 1072375 A1 HK1072375 A1 HK 1072375A1 HK 05105116 A HK05105116 A HK 05105116A HK 1072375 A1 HK1072375 A1 HK 1072375A1
Authority
HK
Hong Kong
Prior art keywords
smooth muscle
botulinum toxin
muscle disorders
neurotoxic component
treating smooth
Prior art date
Application number
HK05105116.3A
Other languages
English (en)
Inventor
Roger K Aoki
Michael W Grayston
Steven R Carlson
Judith M Leon
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22634387&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1072375(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1072375A1 publication Critical patent/HK1072375A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK05105116.3A 1993-12-28 2005-06-20 Use of the neurotoxic component of botulinum toxin for treating smooth muscle disorders HK1072375A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17399693A 1993-12-28 1993-12-28

Publications (1)

Publication Number Publication Date
HK1072375A1 true HK1072375A1 (en) 2005-08-26

Family

ID=22634387

Family Applications (6)

Application Number Title Priority Date Filing Date
HK01103981A HK1033274A1 (en) 1993-12-28 2001-06-11 Botulinum toxins for treating dystonia
HK04107484.4A HK1064599A1 (en) 1993-12-28 2004-09-28 Use of botulinum toxins against sweating in humans
HK05103646A HK1070831A1 (en) 1993-12-28 2005-04-28 Neurotoxic component of botulinum toxins for treating cervical dystonia
HK05103928A HK1071071A1 (en) 1993-12-28 2005-05-10 Neurotoxic component of botulinum toxin for modulating cholinergic controlled secretions
HK05105116.3A HK1072375A1 (en) 1993-12-28 2005-06-20 Use of the neurotoxic component of botulinum toxin for treating smooth muscle disorders
HK07112425A HK1106700A1 (en) 1993-12-28 2007-11-14 Use of botulinum toxin for the manufacture of a medicament for reducing low back pain

Family Applications Before (4)

Application Number Title Priority Date Filing Date
HK01103981A HK1033274A1 (en) 1993-12-28 2001-06-11 Botulinum toxins for treating dystonia
HK04107484.4A HK1064599A1 (en) 1993-12-28 2004-09-28 Use of botulinum toxins against sweating in humans
HK05103646A HK1070831A1 (en) 1993-12-28 2005-04-28 Neurotoxic component of botulinum toxins for treating cervical dystonia
HK05103928A HK1071071A1 (en) 1993-12-28 2005-05-10 Neurotoxic component of botulinum toxin for modulating cholinergic controlled secretions

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK07112425A HK1106700A1 (en) 1993-12-28 2007-11-14 Use of botulinum toxin for the manufacture of a medicament for reducing low back pain

Country Status (9)

Country Link
EP (23) EP1602379A1 (xx)
JP (33) JP3238154B2 (xx)
AU (1) AU688452B2 (xx)
CA (2) CA2682117A1 (xx)
DE (23) DE69435270D1 (xx)
ES (18) ES2207910T5 (xx)
FR (1) FR08C0034I1 (xx)
HK (6) HK1033274A1 (xx)
WO (1) WO1995017904A2 (xx)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
JPH08511536A (ja) 1993-06-10 1996-12-03 アラーガン、インコーポレイテッド 複数の血清型のボツリヌス毒素により、神経筋疾患および症状を処置する方法
DE69435270D1 (de) * 1993-12-28 2010-04-01 Allergan Inc Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
ES2238969T3 (es) * 1994-05-09 2005-09-16 William J. Binder Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas.
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) 1996-07-08 2004-03-02 University Of Massachusetts Proteins within the type E botulinum neurotoxin complex
US6780413B2 (en) 1996-09-19 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
AU2008201535C1 (en) * 1997-07-15 2013-09-12 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
AU2006225233C1 (en) * 1997-07-15 2011-02-10 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
ES2385130T3 (es) 1997-07-15 2012-07-18 The Regents Of The University Of Colorado, A Body Corporate Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
AU2340299A (en) 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6328977B1 (en) * 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
WO2002009743A1 (en) * 2000-08-02 2002-02-07 Allergan Sales, Inc. Method for treating a neoplasm
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
KR20030018827A (ko) * 2001-08-31 2003-03-06 서구일 Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
KR20050061541A (ko) * 2002-10-15 2005-06-22 알러간, 인코포레이티드 보툴리눔 독소 치과 치료 및 시술
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
MXPA05009425A (es) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica.
MXPA05009424A (es) 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento de chalazion cronico y hordeolum con la toxina botulinica.
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
FR2857595B1 (fr) * 2003-07-18 2005-10-07 Sod Conseils Rech Applic Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US7276244B2 (en) 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
CA2555939A1 (en) * 2004-02-12 2005-09-01 Philip Radovic Treatment of abnormalities of the first metatarsophalangeal joint of the foot
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
CA3031270A1 (en) 2004-03-03 2005-12-22 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
EP1729821B1 (en) 2004-03-03 2013-07-17 ReVance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1861112A4 (en) 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS
EP1747782A1 (en) 2005-07-19 2007-01-31 Cesare Montecucco Products for topical application comprising lysophospholipids and fatty acids
US7910116B2 (en) 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
CN101355962A (zh) 2005-11-17 2009-01-28 雷文斯治疗公司 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
US7655625B2 (en) 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
WO2008121067A1 (en) 2007-03-30 2008-10-09 Anders Fagergren Quantification of mechanical and neural contributions to spasticity
EP2178549B1 (en) 2007-07-26 2016-09-14 Revance Therapeutics, Inc. Antimicrobial peptide and compositions thereof
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
US8470337B2 (en) 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
DK3332805T3 (da) 2008-12-31 2022-05-16 Revance Therapeutics Inc Injicerbare botulinumtoksinformuleringer
BRPI1015938A2 (pt) 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
RU2545453C2 (ru) * 2013-03-21 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения переломов нижней челюсти
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
KR101677710B1 (ko) * 2014-06-30 2016-11-21 (주)메디톡스 보툴리눔 독소를 유효성분으로 포함하는 골관절염 치료용 약제학적 조성물 및 그를 이용한 골관절염 치료 방법
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
KR20240023684A (ko) * 2016-09-13 2024-02-22 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
WO2020047159A1 (en) * 2018-08-28 2020-03-05 Ira Sanders Skin therapeutics
RU2732204C1 (ru) * 2020-01-28 2020-09-14 Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" Способ лечения головных болей напряжения по Гурову-Левину
CN116348480A (zh) * 2020-10-07 2023-06-27 普罗塔克斯公司 肉毒杆菌毒素的真空干燥方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
AU4646393A (en) * 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
JP4381477B2 (ja) * 1993-01-15 2009-12-09 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド 筋膜疼痛症候群の治療方法
JPH08511536A (ja) * 1993-06-10 1996-12-03 アラーガン、インコーポレイテッド 複数の血清型のボツリヌス毒素により、神経筋疾患および症状を処置する方法
JP4249802B2 (ja) * 1993-06-10 2009-04-08 アラーガン、インコーポレイテッド 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
DE69435270D1 (de) * 1993-12-28 2010-04-01 Allergan Inc Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ES2238969T3 (es) * 1994-05-09 2005-09-16 William J. Binder Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas.
JP2001104991A (ja) * 1999-10-12 2001-04-17 Toyoaki Kubota 循環水の有機質除去剤

Also Published As

Publication number Publication date
WO1995017904A2 (en) 1995-07-06
ES2163090T3 (es) 2002-01-16
DE69435116D1 (de) 2008-08-21
DE69435276D1 (de) 2010-04-08
JP3238154B2 (ja) 2001-12-10
JP2002114706A (ja) 2002-04-16
DE69435330D1 (de) 2011-01-27
CA2180011A1 (en) 1995-07-06
DE69433394D1 (de) 2004-01-15
EP1591129A2 (en) 2005-11-02
JP2012197287A (ja) 2012-10-18
EP1147775B1 (en) 2009-03-04
AU1516295A (en) 1995-07-17
JP2006160754A (ja) 2006-06-22
EP1103267B1 (en) 2004-09-15
DE69434610D1 (de) 2008-08-21
EP1757325B1 (en) 2010-11-03
DE69435302D1 (de) 2010-08-26
DE69435194D1 (de) 2009-04-16
DE69434008D1 (de) 2004-10-21
DE69435149D1 (de) 2008-11-20
DE69434008T2 (de) 2005-09-22
DE69433394T2 (de) 2004-10-14
EP1366770B1 (en) 2005-07-27
EP1421948A3 (en) 2004-06-16
JPH09507234A (ja) 1997-07-22
EP1602379A1 (en) 2005-12-07
EP1147776B1 (en) 2010-12-15
EP0770395A1 (en) 1997-05-02
EP1005867B2 (en) 2010-02-17
DE69435243D1 (de) 2009-11-19
JP2012167115A (ja) 2012-09-06
DE69428813D1 (de) 2001-11-29
EP0770395B1 (en) 2001-10-24
DE69427869D1 (de) 2001-09-06
EP1103267A1 (en) 2001-05-30
FR08C0034I1 (fr) 2008-09-26
EP1486214A1 (en) 2004-12-15
DE69427869T2 (de) 2002-04-11
ES2207910T5 (es) 2010-05-21
EP1147776A3 (en) 2003-01-15
JP2002104991A (ja) 2002-04-10
EP2027872B1 (en) 2010-07-14
ES2223393T3 (es) 2005-03-01
JP2012167117A (ja) 2012-09-06
DE122008000043I1 (de) 2008-11-20
EP1790352B1 (en) 2008-07-09
DE69435321D1 (de) 2010-12-16
ES2309973T3 (es) 2008-12-16
JP2002097156A (ja) 2002-04-02
JP2002087984A (ja) 2002-03-27
HK1070831A1 (en) 2005-06-30
EP1366770A3 (en) 2004-03-17
JP2008056682A (ja) 2008-03-13
DE69434319T2 (de) 2006-03-09
ES2332905T3 (es) 2010-02-15
EP1147775A2 (en) 2001-10-24
JP2010209105A (ja) 2010-09-24
DE69434319T3 (de) 2011-02-17
EP1421948B1 (en) 2008-10-08
DE69434610T2 (de) 2008-11-27
DE69434443D1 (de) 2005-09-01
EP1563843B1 (en) 2013-08-07
EP1757325A1 (en) 2007-02-28
JP2002087986A (ja) 2002-03-27
EP1502600B1 (en) 2009-10-07
EP1005867B1 (en) 2003-12-03
EP1366771B1 (en) 2008-03-26
JP2002087988A (ja) 2002-03-27
EP1010431A2 (en) 2000-06-21
JP2008056683A (ja) 2008-03-13
ES2237033T3 (es) 2005-07-16
EP1598077A1 (en) 2005-11-23
JP2010202660A (ja) 2010-09-16
EP1488803A1 (en) 2004-12-22
EP1072270A2 (en) 2001-01-31
JP2012167114A (ja) 2012-09-06
ES2339865T3 (es) 2010-05-26
DE69434535T2 (de) 2006-07-20
EP1421948A2 (en) 2004-05-26
EP1790352A1 (en) 2007-05-30
ES2242126T3 (es) 2005-11-01
JP2002104990A (ja) 2002-04-10
ES2251651T3 (es) 2008-07-16
EP1591129A3 (en) 2005-11-16
EP1502600A1 (en) 2005-02-02
EP0737074A1 (en) 1996-10-16
HK1071071A1 (en) 2005-07-08
EP1005867A3 (en) 2001-06-13
EP1010431A3 (en) 2001-05-16
JP2013006865A (ja) 2013-01-10
ES2159624T3 (es) 2001-10-16
HK1106700A1 (en) 2008-03-20
EP1598077B1 (en) 2009-11-04
HK1064599A1 (en) 2005-02-04
EP1005867A2 (en) 2000-06-07
DE69433394T3 (de) 2010-08-12
EP1072270B1 (en) 2005-10-19
EP1600163A1 (en) 2005-11-30
EP0737074B1 (en) 2001-08-01
AU688452B2 (en) 1998-03-12
JP2006160753A (ja) 2006-06-22
EP1366771A3 (en) 2003-12-10
ES2347384T3 (es) 2010-10-28
ES2237033T5 (es) 2010-10-29
CA2180011C (en) 2001-05-15
JP2008037877A (ja) 2008-02-21
DE69434443T2 (de) 2006-05-24
JP2008063339A (ja) 2008-03-21
EP1563843A1 (en) 2005-08-17
DE69434511D1 (de) 2006-03-02
DE69434319D1 (de) 2005-05-04
EP1010431B1 (en) 2005-03-30
JP2002087987A (ja) 2002-03-27
EP1072270A3 (en) 2002-08-07
ES2334357T3 (es) 2010-03-09
JP2012188433A (ja) 2012-10-04
EP1147775A3 (en) 2003-01-15
DE69435249D1 (de) 2009-12-17
ES2319860T3 (es) 2009-05-14
EP1366771A2 (en) 2003-12-03
DE69428813T2 (de) 2002-04-04
ES2340172T3 (es) 2010-05-31
JP2010202659A (ja) 2010-09-16
EP1488803B1 (en) 2008-03-26
JP2006160755A (ja) 2006-06-22
JP2010202661A (ja) 2010-09-16
ES2247575T3 (es) 2006-03-01
EP1366770A2 (en) 2003-12-03
JP2008031176A (ja) 2008-02-14
DE69435270D1 (de) 2010-04-01
ES2248780T3 (es) 2008-06-16
DE69434540D1 (de) 2009-03-26
JP2002097145A (ja) 2002-04-02
DE69434511T2 (de) 2006-07-13
EP1010431B2 (en) 2010-07-14
DE122008000042I1 (de) 2009-01-02
ES2246800T3 (es) 2006-03-01
EP1477183A1 (en) 2004-11-17
JP2006160756A (ja) 2006-06-22
ES2207910T3 (es) 2004-06-01
EP1147776A2 (en) 2001-10-24
HK1033274A1 (en) 2001-08-24
EP1600163B1 (en) 2010-02-17
DE122009000038I1 (de) 2009-11-05
JP2002068989A (ja) 2002-03-08
JP2012167116A (ja) 2012-09-06
ES2355491T3 (es) 2011-03-28
EP2027872A1 (en) 2009-02-25
EP1591129B1 (en) 2010-02-24
DE69434540T2 (de) 2009-06-18
CA2682117A1 (en) 1995-07-06
DE69434535D1 (de) 2005-12-08
JP2007262086A (ja) 2007-10-11
EP1477183B1 (en) 2005-11-02
WO1995017904A3 (en) 1995-10-19
JP2002087985A (ja) 2002-03-27

Similar Documents

Publication Publication Date Title
HK1072375A1 (en) Use of the neurotoxic component of botulinum toxin for treating smooth muscle disorders
EP0814814A4 (en) METHODS OF TREATING THROMBOSIS
ZA945545B (en) Psoriasis treatment
EP0729361A4 (en) METHOD FOR TREATING NEUROLOGICAL DISEASES
HK1014563A1 (en) Method and apparatus for the surface treatment of parts
EP0479025A3 (en) Device for the treatment of non-circular surfaces of work-pieces
EP0510503A3 (en) Process for the treatment of surfaces
ZA964523B (en) Iron oxide-containing one or two component polyurethane lacquer for the coating of elastomers its production and use
GB2284706B (en) Treatment apparatus
IL112469A0 (en) Composition for the treatment of an epidermal disorder
EP0610669A3 (de) Vorrichtung zum Behandeln von Körperteilen mit Vibrationen.
GB9309239D0 (en) Fluid treatment process
EP0665077A4 (en) GEAR FINISHING APPARATUS.
GB9317306D0 (en) Effluent treatment
GB9107312D0 (en) Process for the treatment of effluent
GB9200894D0 (en) Effluent treatment apparatus
GB9311500D0 (en) Fluid treatment apparatus
GB2279070B (en) Process for the treatment of sewage
AU7010598A (en) Botulinum toxins for treating various disorders and associated pain
GB9325664D0 (en) Fluid treatment apparatus
GB9320545D0 (en) Fluid treatment apparatus
GB9320546D0 (en) Fluid treatment apparatus
GB9311269D0 (en) Fluid treatment apparatus
GB9410744D0 (en) Fluid treatment apparatus
GB9320538D0 (en) Fluid treatment apparatus

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF INVENTOR FROM AOKI, ROGER TO AOKI, ROGER K.

PE Patent expired

Effective date: 20141215